Clinical effect of atorvastatin combined with trimetazidine on patients with coronary heart disease and its influence on cardiac function
Objective To analyze the clinical effect of atorvastatin combined with trimetazidine on patients with coronary heart disease and its influence on cardiac function.Methods 88 patients with coronary heart disease were randomly divided into a control group and an observation group,with 44 cases in each group.The control group was treated with atorvastatin,and the observation group was treated with trimetazidine on the basis of the treatment of the control group.Patients in both groups were compared in terms of therapeutic effect,cardiac function indicators[left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF)],oxidative stress indicators[malondialdehyde(MDA),superoxide dismutase(SOD)],inflammatory markers[interleukin-6(IL-6),C-reactive protein(CRP),and tumor necrosis factor-α(TNF-α)]levels.Results The total effective rate of 95.45%in the observation group was significantly higher than 81.82%in the control group,and the difference was statistically significant(P＜0.05).After treatment,the observation group had LVESD of(35.06±2.45)mm and LVEDD of(45.08±3.13)mm,which were smaller than(40.78±2.48)and(49.12±3.01)mm in the control group;the observation group had significantly higher LVEF of(48.97±3.58)%than(43.37±3.86)%in the control group;the difference was statistically significant(P＜0.05).After treatment,the observation group had lower MDA of(3.27±0.83)μmol/L than(8.28±1.84)μmol/L in the control group,and higher SOD of(120.31±24.42)U/ml than(76.43±17.32)U/ml in the control group.The difference was statistically significant(P＜0.05).Before treatment,there was no significant difference in IL-6,CRP and TNF-α between the two groups(P＞0.05).After treatment,the observation group had IL-6 of(43.61±5.48)ng/L,CRP of(10.51±2.68)mg/L,and TNF-α of(109.84±28.46)ng/L,which were lower than(51.52±6.17)ng/L,(14.17±3.53)mg/L,and(157.78±48.51)ng/L in the control group,and the difference was statistically significant(P＜0.05).Conclusion For patients with coronary heart disease,the combined application of atorvastatin and trimetazidine can enhance the efficacy,improve the cardiac function and oxidative stress indicators of patients,reduce inflammation,and effectively promote their early recovery,which is worth promoting clinically.
AtorvastatinTrimetazidineCoronary heart diseaseCardiac function
NETL
NSTL
万方数据
维普
